Tolerance to drug-induced cell death favours the acquisition of multidrug resistance in Leishmania

Cell Death and Disease

Volumn 2, Issue 9, 2011, Pages

  Moreira, W ^a   Leprohon, P ^a   Ouellette, M ^a  

^a LAVAL UNIVERSITY   (Canada)

Author keywords

Apoptosis; Leishmania; Multidrug resistance; Reactive oxygen species

Indexed keywords

AMPHOTERICIN B; ANTILEISHMANIAL AGENT; ANTIMONY; METHOTREXATE; MILTEFOSINE; PAROMOMYCIN; REACTIVE OXYGEN METABOLITE;

APOPTOSIS; ARTICLE; CELL DEATH; CONTROLLED STUDY; DRUG REEXPOSURE; DRUG TOLERANCE; LEISHMANIA INFANTUM; MULTIDRUG RESISTANCE; MUTANT; NONHUMAN; PRIORITY JOURNAL;

AMPHOTERICIN B; ANTIMONY; ANTIPROTOZOAL AGENTS; APOPTOSIS; CELL DEATH; DRUG RESISTANCE, MULTIPLE; DRUG TOLERANCE; LEISHMANIA INFANTUM; METHOTREXATE; PAROMOMYCIN; PHOSPHORYLCHOLINE; REACTIVE OXYGEN SPECIES;

LEISHMANIA INFANTUM; PROTOZOA;

EID: 80053395366     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2011.83     Document Type: Article

References (44)

1. Kohanski MA, Dwyer DJ, Collins JJ. How antibiotics kill bacteria: from targets to networks. Nat Rev Microbiol 2010; 8: 423-435.
2. Baguley BC. Multidrug resistance in cancer. Methods Mol Biol 2010; 596: 1-14.
3. Dive C, Hickman JA. Drug-target interactions: only the first step in the commitment to a programmed cell death? Br J Cancer 1991; 64: 192-196.
4. Mehta A, Shaha C. Mechanism of metalloid-induced death in Leishmania spp.: role of iron, reactive oxygen species, Ca2+, and glutathione. Free Radic Biol Med 2006; 40: 1857-1868.
5. Roy A, Ganguly A, BoseDasgupta S, Das BB, Pal C, Jaisankar P et al. Mitochondriadependent reactive oxygen species-mediated programmed cell death induced by 3, 30-diindolylmethane through inhibition of F0F1-ATP synthase in unicellular protozoan parasite Leishmania donovani. Mol Pharmacol 2008; 74: 1292-1307.
6. Sen R, Bandyopadhyay S, Dutta A, Mandal G, Ganguly S, Saha P et al. Artemisinin triggers induction of cell-cycle arrest and apoptosis in Leishmania donovani promastigotes. J Med Microbiol 2007; 56: 1213-1218. (Pubitemid 47477194)
7. Vergnes B, Gourbal B, Girard I, Sundar S, Drummelsmith J, Ouellette M. A proteomics screen implicates HSP83 and a small kinetoplastid calpain-related protein in drug resistance in Leishmania donovani clinical field isolates by modulating drug-induced programmed cell death. Mol Cell Proteomics 2007; 6: 88-101. (Pubitemid 46152694)
8. Zangger H, Mottram JC, Fasel N. Cell death in Leishmania induced by stress and differentiation: programmed cell death or necrosis? Cell Death Differ 2002; 9: 1126-1139.
9. Ouellette M, Drummelsmith J, Papadoulou B. Leishmaniasis: drugs in the clinic, resistance and new developments. Drug Resist Updat 2004; 7: 257-266. (Pubitemid 39469098)
10. Sundar S, Jha TK, Thakur CP, Sinha PK, Bhattacharya SK. Injectable paromomycin for Visceral leishmaniasis in India. N Engl J Med 2007; 356: 2571-2581. (Pubitemid 46961002)
11. Baiocco P, Colotti G, Franceschini S, Ilari A. Molecular basis of antimony treatment in leishmaniasis. J Med Chem 2009; 52: 2603-2612.
12. Berman JD, Gallalee JV, Best JM. Sodium stibogluconate (Pentostam) inhibition of glucose catabolism via the glycolytic pathway, and fatty acid beta-oxidation in Leishmania mexicana amastigotes. Biochem Pharmacol 1987; 36: 197-201. (Pubitemid 17004915)
13. Chakraborty AK, Majumder HK. Mode of action of pentavalent antimonials: specific inhibition of type I DNA topoisomerase of Leishmania donovani. Biochem Biophys Res Commun 1988; 152: 605-611.
14. Cunningham ML, Fairlamb AH. Trypanothione reductase from Leishmania donovani. Purification, characterisation and inhibition by trivalent antimonials. Eur J Biochem 1995; 230: 460-468.
15. Lucumi A, Robledo S, Gama V, Saravia NG. Sensitivity of Leishmania viannia panamensis to pentavalent antimony is correlated with the formation of cleavable DNA-protein complexes. Antimicrob Agents Chemother 1998; 42: 1990-1995. (Pubitemid 28363081)
16. Sereno D, Holzmuller P, Mangot I, Cuny G, Ouaissi A, Lemesre JL. Antimonial-mediated DNA fragmentation in Leishmania infantum amastigotes. Antimicrob Agents Chemother 2001; 45: 2064-2069. (Pubitemid 32591699)
17. Sudhandiran G, Shaha C. Antimonial-induced increase in intracellular Ca2+ through non-selective cation channels in the host and the parasite is responsible for apoptosis of intracellular Leishmania donovani amastigotes. J Biol Chem 2003; 278: 25120-25132. (Pubitemid 37548676)
18. Wyllie S, Cunningham ML, Fairlamb AH. Dual action of antimonial drugs on thiol redox metabolism in the human pathogen Leishmania donovani. J Biol Chem 2004; 279: 39925-39932. (Pubitemid 39258265)
19. Lux H, Heise N, Klenner T, Hart D, Opperdoes FR. Ether-lipid (alkyl-phospholipid) metabolism and the mechanism of action of ether-lipid analogues in Leishmania. Mol Biochem Parasitol 2000; 111: 1-14.
20. Rakotomanga M, Blanc S, Gaudin K, Chaminade P, Loiseau PM. Miltefosine affects lipid metabolism in Leishmania donovani promastigotes. Antimicrob Agents Chemother 2007; 51: 1425-1430. (Pubitemid 46586825)
21. Ramos H, Valdivieso E, Gamargo M, Dagger F, Cohen BE. Amphotericin B kills unicellular leishmanias by forming aqueous pores permeable to small cations and anions. J Membr Biol 1996; 152: 65-75. (Pubitemid 26281057)
22. Goad LJ, Holz Jr GG, Beach DH. Sterols of Leishmania species. Implications for biosynthesis. Mol Biochem Parasitol 1984; 10: 161-170. (Pubitemid 14187833)
23. Fernandez MM, Malchiodi EL, Algranati ID. Differential effects of paromomycin on ribosomes of Leishmania mexicana and mammalian cells. Antimicrob Agents Chemother 2011; 55: 86-93.
24. Maarouf M, de Kouchkovsky Y, Brown S, Petit PX, Robert-Gero M. In vivo interference of paromomycin with mitochondrial activity of Leishmania. Exp Cell Res 1997; 232: 339-348. (Pubitemid 27194047)
25. Maarouf M, Lawrence F, Croft SL, Robert-Gero M. Ribosomes of Leishmania are a target for the aminoglycosides. Parasitol Res 1995; 81: 421-425.
26. Paris C, Loiseau PM, Bories C, Breard J. Miltefosine induces apoptosis-like death in Leishmania donovani promastigotes. Antimicrob Agents Chemother 2004; 48: 852-859. (Pubitemid 38280335)
27. Verma NK, Dey CS. Possible mechanism of miltefosine-mediated death of Leishmania donovani. Antimicrob Agents Chemother 2004; 48: 3010-3015. (Pubitemid 38992329)
28. Moreira W, Leblanc E, Ouellette M. The role of reduced pterins in resistance to reactive oxygen and nitrogen intermediates in the protozoan parasite Leishmania. Free Radic Biol Med 2009; 46: 367-375.
29. Arnoult D, Akarid K, Grodet A, Petit PX, Estaquier J, Ameisen JC. On the evolution of programmed cell death: apoptosis of the unicellular eukaryote Leishmania major involves cysteine proteinase activation and mitochondrion permeabilization. Cell Death Differ 2002; 9: 65-81. (Pubitemid 34071994)
30. Nare B, Luba J, Hardy LW, Beverley S. New approaches to Leishmania chemotherapy: pteridine reductase 1 (PTR1) as a target and modulator of antifolate sensitivity. Parasitology 1997; 114(Suppl): S101-S110.
31. Ouellette M, Drummelsmith J, El-Fadili A, Kundig C, Richard D, Roy G. Pterin transport and metabolism in Leishmania and related trypanosomatid parasites. Int J Parasitol 2002; 32: 385-398. (Pubitemid 34159125)
32. Mukhopadhyay P, Rajesh M, Hasko G, Hawkins BJ, Madesh M, Pacher P. Simultaneous detection of apoptosis and mitochondrial superoxide production in live cells by flow cytometry and confocal microscopy. Nat Protoc 2007; 2: 2295-2301. (Pubitemid 351565867)
33. Kohanski MA, Dwyer DJ, Hayete B, Lawrence CA, Collins JJ. A common mechanism of cellular death induced by bactericidal antibiotics. Cell 2007; 130: 797-810. (Pubitemid 47332566)
34. Kroemer G, Galluzzi L, Vandenabeele P, Abrams J, Alnemri ES, Baehrecke EH et al. Classification of cell death: recommendations of the Nomenclature Committee on Cell Death 2009. Cell Death Differ 2009; 16: 3-11.
35. Smirlis D, Duszenko M, Ruiz AJ, Scoulica E, Bastien P, Fasel N et al. Targeting essential pathways in trypanosomatids gives insights into protozoan mechanisms of cell death. Parasit Vectors 2010; 3: 107.
36. Croft SL, Sundar S, Fairlamb AH. Drug Resistance in Leishmaniasis. Clin Microb Rev 2006; 19: 111-126. (Pubitemid 43157649)
37. Ouellette M, Drummelsmith J, Papadopoulou B. Leishmaniasis: drugs in the clinic, resistance and new developments. Drug Resist Updat 2004; 7: 257-266. (Pubitemid 39469098)
38. Mukhopadhyay R, Dey S, Xu N, Gage D, Lightbody J, Ouellette M et al. Trypanothione overproduction and resistance to antimonials and arsenicals in Leishmania. Proc Natl Acad Sci USA 1996; 93: 10383-10387. (Pubitemid 26314631)
39. Wyllie S, Mandal G, Singh N, Sundar S, Fairlamb AH, Chatterjee M. Elevated levels of tryparedoxin peroxidase in antimony unresponsive Leishmania donovani field isolates. Mol Biochem Parasitol 2010; 173: 162-164.
40. Kohanski MA, DePristo MA, Collins JJ. Sublethal antibiotic treatment leads to multidrug resistance via radical-induced mutagenesis. Mol Cell 2010; 37: 311-320.
41. Kumar D, Kulshrestha A, Singh R, Salotra P. In vitro susceptibility of field isolates of Leishmania donovani to Miltefosine and Amphotericin B: correlation with sodium antimony gluconate susceptibility and implications for treatment in areas of endemicity. Antimicrob Agents Chemother 2009; 53: 835-838.
42. Chappuis F, Sundar S, Hailu A, Ghalib H, Rijal S, Peeling RW et al. Visceral leishmaniasis: What are the needs for diagnosis, treatment and control? Nat Rev Microbiol 2007; 5: 873-882. (Pubitemid 47578388)
43. Sacks DL, Perkins PV. Development of infective stage Leishmania promastigotes within phlebotomine sand flies. Am J Trop Med Hyg 1985; 34: 456-459. (Pubitemid 15041367)
44. Mukherjee A, Roy G, Guimond C, Ouellette M. The gamma-glutamylcysteine synthetase gene of Leishmania is essential and involved in response to oxidants. Mol Microbiol 2009; 74: 914-927.